Imugene Limited (IMU.AX)
| Previous close | 0.1800 |
| Open | 0.1850 |
| Bid | 0.1950 x 102397000 |
| Ask | 0.2000 x 716752400 |
| Day's range | 0.1800 - 0.2050 |
| 52-week range | 0.1300 - 0.6250 |
| Volume | |
| Avg. volume | 22,601,570 |
| Market cap | 1.144B |
| Beta (5Y monthly) | 2.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0050 |
| Earnings date | 28 Aug 2022 - 01 Sept 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.55 |
- Business Wire
City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors
SYDNEY & LOS ANGELES, May 17, 2022--Imugene Limited and City of Hope's first patient was dosed in a clinical trial evaluating the safety of new cancer-killing virus CF33-hNIS VAXINIA.
- GlobeNewswire
Imugene Announces Clinical Trial Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to Evaluate HER-Vaxx in Combination with Pembrolizumab for Treatment of Gastric Cancer
New clinical trial supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA for Phase 2 clinical study (nextHERIZON) in HER-2 positive gastric or gastroesophageal junction adenocarcinomasnextHERIZON will assess HER-Vaxx in combination with chemotherapy or pembrolizumab in patients with HER-2 positive gastric cancer that have failed trastuzumab SYDNEY, Australia, March 14, 2022 (GLOBE NEWSWIRE) -- Imugene (ASX: IMU) today announced a new clinical trial collaboration and s
- Simply Wall St.
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Imugene ( ASX:IMU...
